Roche: Billion-dollar investment in the future market of fatty liver!

Roche is acquiring the US biotech company 89bio in a billion-dollar transaction, thereby expanding its portfolio with a highly developed treatment for fatty liver disease. This move enhances Roche's presence in one of the industry's fastest-growing segments and clearly positions it in the competition for innovative therapies for metabolic-associated diseases. Pegozafermin as a beacon of hope for millions of MASH patients The drug Pegozafermin from 89bio is expected to fundamentally change the treatment of metabolic-associated steatohepatitis...